Recent announcements from three biotechnology and pharmaceutical companies reflect the increasing interest in and tractability of myotonic dystrophy for therapy development. Short summaries and links to the press releases are provided here.
News
04/11/2019 - 10:51am
Dr. Vincent Dion awarded $250,000 grant to pursue gene editing technology development to find a cure for DM.
04/11/2019 - 10:46am
The Myotonic Dystrophy Clinical Research Network (DMCRN) sites are currently conducting a critically-important research study designed to help drug developers successfully design clinical trials and understand how to assess the efficacy of potential therapies.
03/19/2019 - 10:30am
Disorders of sleep and breathing are well characterized for DM1, but what about DM2?
03/19/2019 - 10:25am
A new review looks at the opportunities and hurdles for genome editing in neuromuscular disease.
